文献速递呼吸道感染呼吸危重症与机械通气

头孢曲松预防院外心脏骤停后昏迷患者早发性肺炎:一项初步随机对照试验及耐药基因组评估(PROTECT)

Ceftriaxone to Prevent Early-Onset Pneumonia in Comatose Patients Following Out-of-Hospital Cardiac Arrest: A Pilot Randomized Controlled Trial and Resistome Assessment (PROTECT).
PubMed 文献 · Chest · 2025-08-28

本研究为初步随机对照试验,纳入院外心脏骤停后昏迷且接受目标温度管理、入院时无肺炎临床诊断的幸存者,随机接受头孢曲松2g或安慰剂每12小时一次共3天。主要结局为插管后≤4天经盲法裁定确认的早发性肺炎。结果显示头孢曲松组早发性肺炎发生10例(38%),安慰剂组18例(69%)(风险比0.57;95%CI 0.21-1.001;开放标签抗生素使用头孢曲松组14例(54%),安慰剂组22例(85%)(风险比0.64;95%CI 0.43-0.94)。调整基线耐药基因丰度差异后,头孢曲松组获得ICU常用抗生素耐药基因显著少于安慰剂组(发生率比0.30;95%CI 0.13-0.70)。两组均未报告严重药物不良反应。

要点

  • 头孢曲松组开放标签抗生素使用更少(RR 0.64,95%CI 0.43-0.94)。
  • 头孢曲松组获得ICU常用抗生素耐药基因更少(IRR 0.30,95%CI 0.13-0.70)。

核心结论

  • 本试验关于头孢曲松预防对降低院外心脏骤停后早发性肺炎发生率的影响无定论。
  • 头孢曲松与更少的开放标签抗生素使用及更少的ICU常用抗生素耐药基因获得相关。

研究设计与样本

  • 研究为初步随机对照试验,纳入院外心脏骤停后昏迷、接受目标温度管理且入院时无肺炎临床诊断的幸存者。
  • 参与者随机接受头孢曲松2g或匹配安慰剂每12小时一次共3天。
  • 共筛查411例,随机53例(13%),1例退出,最终每组26例分析。
  • 主要结局为插管后≤4天经盲法裁定确认的早发性肺炎。
  • 通过宏基因组测序分析研究药物给药前后直肠拭子中抗生素耐药基因丰度。

主要发现

  • 开放标签抗生素使用于头孢曲松组14例(54%)和安慰剂组22例(85%)(风险比0.64;95%CI 0.43-0.94),其中大多数为广谱抗生素(分别为93%和100%)。
  • 调整给药前耐药基因丰度差异后,头孢曲松组获得ICU常用抗生素耐药基因显著少于安慰剂组(发生率比0.30;95%CI 0.13-0.70)。
  • 两组均未报告严重药物不良反应。

关键数值与推荐

  • 头孢曲松用法:2g每12小时一次,共3天。
  • 主要结局定义:插管后≤4天经盲法裁定确认的早发性肺炎。
  • 开放标签抗生素使用风险比0.64(95%CI 0.43-0.94)。
  • 耐药基因获得发生率比0.30(95%CI 0.13-0.70)。

临床怎么用

  • 对于院外心脏骤停后昏迷并接受目标温度管理的患者,头孢曲松预防早发性肺炎的获益尚不确定。
  • 头孢曲松预防可能减少开放标签抗生素的使用及ICU常用抗生素耐药基因的获得。

局限性

  • 本研究为初步试验,最终分析每组仅26例,样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antibiotic prophylaxis following out-of-hospital cardiac arrest (OHCA) reduces early-onset pneumonia. However, it has an uncertain impact on mortality and noninfectious outcomes, with ongoing concerns about the subsequent development of antibiotic resistance. RESEARCH QUESTION: Does prophylactic ceftriaxone reduce the incidence of early-onset pneumonia without increasing the acquisition of antibiotic resistance genes after OHCA? STUDY DESIGN AND METHODS: Comatose survivors of OHCA treated with targeted temperature management without a clinical diagnosis of pneumonia at admission were randomized to receive ceftriaxone 2 g or matching placebo every 12 hours for 3 days. The primary outcome was early-onset pneumonia occurring ≤ 4 days following intubation confirmed by masked adjudicators. Abundance of antibiotic resistance genes recovered from rectal swabs before and after study drug administration were analyzed with metagenomic sequencing. RESULTS: A total of 411 participants were screened; 53 (13%) were randomized to treatment, and 1 participant withdrew, leaving 26 in each group in the final analysis. Early-onset pneumonia was diagnosed in 10 (38%) participants receiving ceftriaxone and 18 (69%) participants receiving placebo (risk ratio, 0.57; 95% CI, 0.21-1.001; P = .05). Open-label antibiotics were administered to 14 (54%) participants receiving ceftriaxone and 22 (85%) receiving placebo (risk ratio, 0.64; 95% CI, 0.43-0.94); most of the antibiotics were broad-spectrum agents (93% and 100%, respectively). After adjusting for differences in abundance of antibiotic resistance genes prior to study drug administration, participants randomized to receive ceftriaxone acquired significantly fewer antibiotic resistance genes to frequently used antibiotics in the ICU compared with those randomized to receive placebo (incidence risk ratio, 0.30; 95% CI, 0.13-0.70). Serious adverse drug effects were not reported in either treatment group. INTERPRETATION: This trial was inconclusive regarding the impact of ceftriaxone prophylaxis on reducing the incidence of early-onset pneumonia following OHCA. However, ceftriaxone was associated with less frequent administration of open-label antibiotics and reduced acquisition of antibiotic resistance genes to frequently used antibiotics in the ICU. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT04999592; URL: www. CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Gagnon DJ, Burkholder KM, Weissman AJ, et al. Ceftriaxone to Prevent Early-Onset Pneumonia in Comatose Patients Following Out-of-Hospital Cardiac Arrest: A Pilot Randomized Controlled Trial and Resistome Assessment (PROTECT). Chest. 2025. PMID: 40885534. doi:10.1016/j.chest.2025.08.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。